Loading clinical trials...
Loading clinical trials...
A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
Conditions
Interventions
AMG820 and pembrolizumab
Locations
15
United States
Research Site
Atlanta, Georgia, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
New York, New York, United States
Research Site
Philadelphia, Pennsylvania, United States
Start Date
April 14, 2016
Primary Completion Date
January 2, 2019
Completion Date
May 17, 2019
Last Updated
January 20, 2023
NCT07446322
NCT07542041
NCT07541924
NCT07431827
NCT06758401
NCT06427941
Lead Sponsor
AmMax Bio, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions